SCHEMBL1768170

SCHEMBL1768170

O=c1ccccn1Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
KDM4E B2RXH2 3/20 0.57
ALDH1A1 P00352 3/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
MAPK14 Q16539 1/20 0.53
PSMB1 P20618 1/20 0.50
F2 P00734 1/20 0.50
PLG P00747 1/20 0.50
ELANE P08246 1/20 0.50
CTSG P08311 1/20 0.50
CMA1 P23946 1/20 0.50
CTRC Q99895 1/20 0.50
HTT P42858 2/20 0.47
TP53 P04637 1/20 0.47
CYP2D6 P10635 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
GSK3A P49840 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9523272 0.98 KDM4E (0.60) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL9752787 0.93 POLB (0.63) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL9752676 0.88 POLB (0.58) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL1240350 0.86 MAPT (0.56) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL16881026 0.86 POLB (0.56) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL4591947 0.86 POLB (0.61) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL16891528 0.84 MAPT (0.61) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL16246832 0.84 POLB (0.54) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL17457935 0.84 POLB (0.54) POLBNPSR1KDM4EALDH1A1L3MBTL1
SCHEMBL16891381 0.84 POLB (0.54) POLBNPSR1KDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 EP claimed
EP-3365337-A1 PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS Selvita S.A. (PL) 2018-08-29 EP claimed
WO-2017068064-A1 PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS SELVITA S.A. (PL) 2017-04-27 WO claimed
EP-0888349-B1 PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2002-05-22 EP claimed
EP-0888349-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1999-01-07 EP claimed
WO-1997027199-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1997-07-31 WO claimed
US-20260132149-A1 Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith BEONE MEDICINES I GMBH (CH) 2026-05-14 US disclosed
CN-116082237-B Nitrogen-containing heterocyclic compound and preparation method thereof 安徽中医药大学 2025-04-22 CN disclosed
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS AG (CH) 2024-07-25 US disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed
CN-116082237-A Nitrogen-containing heterocyclic compound and preparation method thereof 安徽中医药大学 2023-05-09 CN disclosed
US-20220204838-A1 LONG-AFTERGLOW LUMINESCENT MATERIAL FUDAN UNIVERSITY (CN) 2022-06-30 US disclosed
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2022-06-16 US disclosed
EP-0572450-B1 AZO DYES HAVING A DIAZO COMPONENT FROM THE AMINOBENZOPHENONE SERIES, AS WELL AS BISULPHONATED PYRIDONE COMPOUNDS BASF AG (DE) 1994-10-26 EP disclosed
WO-1991002721-A1 5-(1-AMINOCYCLOHEXYL)-2(1H)-PYRIDINONE AND RELATED COMPOUNDS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1991-03-07 WO disclosed
EP-0406656-A1 Chroman derivatives MERCK PATENT GmbH (DE) 1991-01-09 EP disclosed
US-4695565-A Antibacterial 7β-heterocyclic-cephem MERCK & CO., INC. (US) 1987-09-22 US disclosed
EP-0177897-A2 Antibacterial 7beta-heterocyclic-cephem MERCK & CO. INC. (US) 1986-04-16 EP disclosed
US-4104273-A Derivatives of 3-cyano-pyrid-2-ones ROHM AND HAAS COMPANY (US) 1978-08-01 US disclosed
US-4028084-A Derivatives of 3-carboxy pyrid-2-ones ROHM AND HAAS COMPANY (US) 1977-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES IKZF1, IKZF2, IKZF3 POLB 1858/4885NPSR1 4487/4885KDM4E 345/4885
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 POLB 2712/4885NPSR1 1640/4885KDM4E 249/4885
US-20260132149-A1 Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith MECP2, PRMT5, DNMT1 POLB 334/4885NPSR1 4853/4885KDM4E 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.